公开(公告)号：US11723908B2

公开(公告)日：2023-08-15

申请号：US17051176

申请日：2019-09-17

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding Zhou ,  Ziqiang Cheng

IPC: A61K31/519 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/7068 ,  C07D487/04 ,  C07D519/00 ,  A61K39/395

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/7068 ,  A61K39/3955 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

公开(公告)号：US20240376123A1

公开(公告)日：2024-11-14

申请号：US18290798

申请日：2022-07-19

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding ZHOU ,  Zheng WANG ,  Ziqiang CHENG ,  Shuai CHEN

IPC: C07D498/22 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  A61P35/00 ,  C07D471/22 ,  C07D491/22 ,  C07D513/22 ,  C07D519/00

Abstract: Provided novel compounds useful as KRAS G12D inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

公开(公告)号：US20210386742A1

公开(公告)日：2021-12-16

申请号：US17051176

申请日：2019-09-17

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding ZHOU ,  Ziqiang CHENG

IPC: A61K31/519 ,  A61K39/395 ,  A61K31/7068 ,  C07D487/04 ,  C07D519/00 ,  A61K31/5377 ,  A61P35/00

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

公开(公告)号：US20240207263A1

公开(公告)日：2024-06-27

申请号：US18551188

申请日：2022-03-15

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding ZHOU ,  Ziqiang CHENG ,  Zheng WANG

IPC: A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  A61N5/10 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

CPC classification number: A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  A61N5/10 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

Abstract: The specification relates to imidazo [4,5-c] cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The specification also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

公开(公告)号：US12226414B2

公开(公告)日：2025-02-18

申请号：US17274781

申请日：2019-09-16

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding Zhou ,  Ziqiang Cheng

IPC: A61K31/5025 ,  A61K31/5377 ,  C07D487/04

Abstract: The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

公开(公告)号：US20230293533A1

公开(公告)日：2023-09-21

申请号：US18319509

申请日：2023-05-18

Applicant: SUZHOU ZANRONG PHARMA LIMITED

Inventor： Ding ZHOU ,  Ziqiang CHENG

IPC: A61K31/519 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/7068 ,  A61K39/395 ,  C07D487/04 ,  C07D519/00

CPC classification number: A61K31/519 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/7068 ,  A61K39/3955 ,  C07D487/04 ,  C07D519/00

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.